Search results for "Immunological"

showing 10 items of 115 documents

TCR signalling network organization at the immunological synapses of murine regulatory T cells.

2017

Regulatory T (Treg) cells require T-cell receptor (TCR) signalling to exert their immunosuppressive activity, but the precise organization of the TCR signalling network compared to conventional T (Tconv) cells remains elusive. By using accurate mass spectrometry and multi-epitope ligand cartography (MELC) we characterized TCR signalling and recruitment of TCR signalling components to the immunological synapse (IS) in Treg cells and Tconv cells. With the exception of Themis which we detected in lower amounts in Treg cells, other major TCR signalling components were found equally abundant, however, their phosphorylation-status notably discriminates Treg cells from Tconv cells. Overall, this s…

0301 basic medicineProteomicsImmunological SynapsesProteomeCD3ImmunologyReceptors Antigen T-Cellchemical and pharmacologic phenomenaBiologyT-Lymphocytes RegulatoryArticleImmunological synapse03 medical and health sciencesT-Lymphocyte SubsetsImmunology and AllergyAnimalsPhosphorylationReceptorCells CulturedCD86Mice Inbred BALB CZAP-70 Protein-Tyrosine KinaseZAP70T-cell receptorCD28hemic and immune systemsImmunological SynapsesCell biology030104 developmental biologyMicroscopy Fluorescencebiology.proteinFemaleSignal TransductionEuropean journal of immunology
researchProduct

PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells

2020

ObjectiveCancer stem cells are responsible for tumour spreading and relapse. Human epidermal growth factor receptor 2 (HER2) expression is a negative prognostic factor in colorectal cancer (CRC) and a potential target in tumours carrying the gene amplification. Our aim was to define the expression of HER2 in colorectal cancer stem cells (CR-CSCs) and its possible role as therapeutic target in CRC resistant to anti- epidermal growth factor receptor (EGFR) therapy.DesignA collection of primary sphere cell cultures obtained from 60 CRC specimens was used to generate CR-CSC mouse avatars to preclinically validate therapeutic options. We also made use of the ChIP-seq analysis for transcriptional…

0301 basic medicineReceptor ErbB-2Colorectal cancerCetuximabcolorectal cancermedicine.disease_cause03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineSettore MED/04 - PATOLOGIA GENERALECancer stem cellstem cellsTumor Cells CulturedmedicineAdjuvant therapyAnimalsHumansEpidermal growth factor receptorProtein kinase BPI3K/AKT/mTOR pathwayPhosphoinositide-3 Kinase InhibitorsMitogen-Activated Protein Kinase Kinasesdrug resistancebiologybusiness.industryGastroenterologyTrastuzumabmedicine.diseaseantibody targeted therapy030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisNeoplastic Stem CellsCancer researchbiology.proteinKRASPhosphatidylinositol 3-KinaseStem cellColorectal Neoplasmsbusiness
researchProduct

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.

2017

Abstract Background The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting. However, it does not accomplish memory formation or permanent defiance of tumors in a therapeutic set-up. As a distinct immunologic approach, CTLA-4 blockade augments systemic immune responses and has shown long-lasting effects in preclinical experiments as well as in clinical trials. Objective The study investigates the vaccination capacity of TCI in combination with the checkpoint inhibitor CTLA-4 in matter…

0301 basic medicineSkin NeoplasmsOvalbuminmedicine.medical_treatmentMelanoma Experimentalchemical and pharmacologic phenomenaDermatologyBiochemistryT-Lymphocytes RegulatoryEpitope03 medical and health sciencesMice0302 clinical medicineImmune systemAntineoplastic Agents ImmunologicalAdjuvants ImmunologicmedicineCytotoxic T cellAnimalsHumansCTLA-4 AntigenMolecular BiologyImiquimodMembrane Glycoproteinsbusiness.industryMelanomahemic and immune systemsDrug SynergismTLR7Immunotherapymedicine.diseaseFlow CytometryXenograft Model Antitumor AssaysPeptide FragmentsMice Inbred C57BLCTL*030104 developmental biologyToll-Like Receptor 7CTLA-4030220 oncology & carcinogenesisImmunologyAminoquinolinesImmunotherapybusinessImmunologic MemoryT-Lymphocytes CytotoxicJournal of dermatological science
researchProduct

Imbalance of immunological synapse-kinapse states reflects tumor escape to immunity in glioblastoma

2018

Since the proper activation of T cells requires the physical interaction with target cells through the formation of immunological synapses (IS), an alteration at this level could be a reason why tumors escape the immune response. As part of their life cycle, it is thought that T cells alternate between a static phase, the IS, and a dynamic phase, the immunological kinapse (IK), depending on high or low antigen sensing. Our investigation performed in tissue samples of human glioma shows that T cells are able to establish synapsing interactions not only with glioma tumorigenic cells, but also with stromal myeloid cells. Particularly, the IS displaying a T cell receptor-rich (TCR-rich) central…

0301 basic medicineStromal cellCD3 ComplexImmunological SynapsesT-LymphocytesT cellAntigen-Presenting CellsImmunological synapse03 medical and health sciencesImaging Three-DimensionalImmune systemAntigenGliomaTumor MicroenvironmentmedicineHumansMyeloid CellsBrain NeoplasmsChemistryGliomaGeneral Medicinemedicine.diseaseImmunological SynapsesCell biology030104 developmental biologymedicine.anatomical_structureTechnical AdvanceTumor EscapeTumor EscapeGlioblastomaJCI Insight
researchProduct

Parallels and differences between innate and adaptive lymphocytes.

2016

Lymphocytes are essential in innate and adaptive immunity. Recent insights suggest that some innate lymphocytes execute functions with adaptive characteristics, while adaptive lymphocytes can operate in ways reminiscent of innate cells. Rather than partitioning lymphocytes according to the type of effector function they execute, we propose that a relevant discrimination relates to the existence of conventional T cells in a naive state. The naive state can be seen as an actively repressed condition that supports T cell diversity and enables the flexible differentiation of effector cells in a manner that best addresses the antigenic challenge. We discuss these considerations in the context of…

0301 basic medicineT cellImmunologyContext (language use)BiologyAdaptive Immunity03 medical and health sciencesImmune systemAntigenImmunitymedicineImmunology and AllergyAnimalsHumansLymphocytesEffectorInnate lymphoid cellModels ImmunologicalCell DifferentiationAcquired immune systemImmunity InnateClone CellsReceptors Antigen030104 developmental biologymedicine.anatomical_structureImmunologyCytokinesNeuroscienceNature immunology
researchProduct

The janus face of NKT cell function in autoimmunity and infectious diseases

2018

Natural killer T cells (NKT) are a subset of T lymphocytes bridging innate and adaptive immunity. These cells recognize self and microbial glycolipids bound to non-polymorphic and highly conserved CD1d molecules. Three NKT cell subsets, type I, II and NKT-like expressing different antigen receptors (TCR) were described and TCR activation promotes intracellular events leading to specific functional activities. NKT can exhibit different functions depending on the secretion of soluble molecules and the interaction with other cell types. NKT cells act as regulatory cells in the defence against infections but, on the other hand, their effector functions can be involved in the pathogenesis of sev…

0301 basic medicineglycolipidsAutoimmunityReviewAdaptive Immunitymedicine.disease_causeAutoimmunityCatalysiimmunologylcsh:Chemistry0302 clinical medicineT-Lymphocyte Subsetslcsh:QH301-705.5SpectroscopyInnate lymphoid cellhemic and immune systemsComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineNKTNatural killer T cellAcquired immune systemComputer Science ApplicationsCell biologyCD1DmicrobesCell typechemical and pharmacologic phenomenaGlycolipidBiologyCD1dCommunicable DiseasesCatalysisInorganic Chemistry03 medical and health sciencesmedicineAnimalsHumansMicrobePhysical and Theoretical ChemistryMolecular BiologyInflammationT-cell receptorOrganic ChemistryModels ImmunologicalAlpha-galactosylceramideAlpha-galactosylceramide; Autoimmunity; CD1d; Glycolipids; Microbes; NKT; Sulfatide; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryImmunity InnateSettore MED/16 - Reumatologia030104 developmental biologylcsh:Biology (General)lcsh:QD1-999biology.proteinNatural Killer T-CellsSulfatideCD8030215 immunology
researchProduct

HIV infection with viro-immunological dissociation in a patient with polycystic kidney disease: Candidate for transplantation?

2016

Highlights • Autosomal dominant polycystic kidney disease is the most common among inherited cystic kidney diseases. • Patients with HIV infection are at risk of developing acute kidney injury and chronic kidney disease. • We provide the first report of HIV infection in a patient with polycystic kidney disease. • Lymphopenia should not contraindicate kidney transplantation in patients with HIV infection.

030232 urology & nephrologyHuman immunodeficiency virus (HIV)Case ReportViro-immunological dissociationmedicine.disease_causeVirological response03 medical and health sciences0302 clinical medicinePolycystic kidney diseaseLymphopeniaPolycystic kidney diseaseMedicine030212 general & internal medicineStage (cooking)Kidney transplantationTransplantationurogenital systembusiness.industryHIV; Lymphopenia; Polycystic kidney disease; Transplantation; Viro-immunological dissociation; Infectious Diseasesvirus diseasesHIVmedicine.diseaseAntiretroviral therapyTransplantationInfectious DiseasesImmunologybusinessIDCases
researchProduct

Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity?

2012

The immune system has important roles in limiting the spread of cancer and shaping the tumor microenvironment. Although the contributions of T helper 17 (Th17) cells (a subtype of CD4(+) T lymphocytes) to autoimmunity and allergy response are well known, their roles in cancer remain ambiguous. Despite adoptive transfer studies indicating that mouse Th17 cells support anticancer immunity, the Th17 cells that naturally infiltrate experimental tumors appear to have a tumor-promoting effect. These contradictory properties can be related to the high degree of plasticity inherent in Th17 cells and their capacity to differentiate into tumoricidal Th1-like cells. Mouse Th17 cells induced by transfo…

Adoptive cell transferAngiogenesisAntigen-Presenting Cellschemical and pharmacologic phenomenaBiologymedicine.disease_causeAutoimmunityMice03 medical and health sciences0302 clinical medicineImmune systemAntigenAntigens CDTransforming Growth Factor betaImmunityNeoplasmsImmune TolerancemedicineAnimals5'-NucleotidaseMolecular Biology030304 developmental biologyImmunity Cellular0303 health sciencesTumor microenvironmentNeovascularization PathologicApyraseModels ImmunologicalCell DifferentiationTh1 Cells3. Good health030220 oncology & carcinogenesisImmunologyCancer researchTh17 CellsMolecular MedicineTransforming growth factorTrends in Molecular Medicine
researchProduct

Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudores…

2017

Abstract Background Response Assessment in Neuro-Oncology Criteria (RANO), are used to asses response to first-line treatment of glioblastoma (GBM). Differentiation between response and pseudoresponse under treatment with Bevacizumab (BVZ) remains challenging. This study evaluates ADC changes in patients with radiographic pseudoresponse under treatment with (BVZ). Methods Patients (n = 40) with recurrent GBM under-treatment with BVZ underwent MRI before, two and four months after treatment with BVZ. In patients with radiological pseudoresponse (n = 11), ADC analyses were performed. Areas with decreasing T1 contrast enhancement (CE) and FLAIR signal decrease were manually selected and compar…

AdultMaleBevacizumabRadiographyPseudoresponseFluid-attenuated inversion recovery030218 nuclear medicine & medical imaging03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineImage Interpretation Computer-AssistedmedicineHumansEffective diffusion coefficientRadiology Nuclear Medicine and imagingIn patientAgedRadiological and Ultrasound TechnologyBrain Neoplasmsbusiness.industryMiddle Agedmedicine.diseaseHyperintensityBevacizumabbody regionsDiffusion Magnetic Resonance ImagingTreatment OutcomeFemaleNeurology (clinical)Neoplasm Recurrence LocalGlioblastomabusinessNuclear medicine030217 neurology & neurosurgerymedicine.drugGlioblastomaJournal of Neuroradiology
researchProduct

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODI…

2021

Abstract Immune checkpoint inhibitors have failed in treating metastatic colorectal cancer (mCRC) patients except those with dMMR/MSI tumors. However, until very recently we had only non-comparative promising data in this population with anti-programmed cell death 1/ programmed cell death ligand 1 (PD1/PD-L1) antibodies alone or combined with anti- cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibodies. This comparative phase II trial (NCT 03186326), conducted in more than 100 centers in France, will include dMMR/MSI mCRC patients with progression after a first-line treatment with chemotherapy ± targeted therapies, to evaluate efficacy and safety of the anti-PDL1 Avelumab versus a s…

AdultMaleOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationECOG Performance StatusAntibodies Monoclonal HumanizedAvelumab03 medical and health sciencesAntineoplastic Agents ImmunologicalClinical Trials Phase II as Topic0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopiceducationRandomized Controlled Trials as TopicChemotherapyeducation.field_of_studyHepatologybusiness.industryGastroenterologyMicrosatellite instabilityImmunotherapymedicine.diseaseProgression-Free SurvivalRegimen030220 oncology & carcinogenesisFemaleMicrosatellite Instability030211 gastroenterology & hepatologyFranceColorectal Neoplasmsbusinessmedicine.drugDigestive and Liver Disease
researchProduct